eduKateSG · Why Science?
Map licensed biological products and their regulatory relationships
Use the FDA Purple Book to distinguish reference products, biosimilars, interchangeable biosimilars, product identity, BLA records, licensure dates and database limits.
Biological medicines can be proteins, antibodies, vaccines, cell therapies, gene therapies and other complex products. The FDA Purple Book provides a searchable database of licensed biological products regulated by CDER and CBER.
For CDER products, the database connects licensed biosimilars and interchangeable biosimilars with their reference products. These labels describe FDA regulatory determinations, so they should be copied precisely rather than replaced with informal words such as identical.
Did you know? An interchangeable biosimilar first meets the biosimilarity standard and then meets additional statutory requirements. Interchangeable status does not mean the product is more effective than its reference product.
This guide explains regulatory information, not personal treatment or substitution. Patients should discuss medicine questions with their pharmacist or prescriber and use current FDA-approved labeling.
Chapter index
Chapters 1–9: product identity, reference and biosimilar roles
- 1. The Purple Book lists licensed biologics
- 2. Biologics differ from conventional small molecules
- 3. Reference products anchor comparison
- 4. Biosimilar is an FDA licensure determination
- 5. Interchangeable is an additional designation
- 6. Interchangeability does not mean superior efficacy
- 7. State law affects pharmacy substitution
- 8. Core names group related products
- 9. Application numbers identify licence records
Chapters 10–17: interchangeability, licences, patents and evidence boundaries
- 10. Licensure dates mark FDA action
- 11. Presentations and strengths matter
- 12. CDER and CBER cover different biologic categories
- 13. Reference-product exclusivity is a separate field
- 14. Patent information has a defined source
- 15. Advanced search filters shape the set
- 16. A database relationship is not a prescribing decision
- 17. Biosimilar literacy supports modern science careers
Biological products need their own licensure and relationship map because they are not described through the Orange Book pathway. The database includes FDA-licensed biological products regulated by CDER and CBER, with product and application information. This supports careful science learning about proteins, manufacturing and regulatory comparison.
Try this
Evidence question: Which FDA center and licence record apply? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Record the application and product identity. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for the purple book lists licensed biologics, its identifier or version context, and one limit that must remain visible.
CHAPTER 2 OF 17 · Identify the biologic
2. Biologics differ from conventional small molecules
The Purple Book lists FDA-licensed biological products and connects biosimilars and interchangeable biosimilars with reference products. Biological products are generally large and complex and can be sensitive to manufacturing conditions. Their regulatory comparison uses biosimilarity standards rather than simple molecular identity. It also separates product licensure from prescribing or state substitution practice.
Try this
Evidence question: Which product type is being examined? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Do not import Orange Book terminology automatically. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for biologics differ from conventional small molecules, its identifier or version context, and one limit that must remain visible.
Biosimilarity and interchangeability are defined regulatory determinations, not casual claims that two products are simply alike. A reference product is the single biological product licensed under the full application pathway against which a proposed biosimilar is evaluated. The database card is a route into FDA information rather than a personal treatment recommendation.
Try this
Evidence question: Which product is named as the reference? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Preserve the reference-product relationship. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for reference products anchor comparison, its identifier or version context, and one limit that must remain visible.
CHAPTER 4 OF 17 · Identify the biologic
4. Biosimilar is an FDA licensure determination
Product identity, application, licensure date and relationship should remain in the same note. A biosimilar is licensed based on a showing that it is highly similar to the reference product with no clinically meaningful differences in safety, purity and potency under the statutory standard. A current access date matters because new products and relationships are added.
Try this
Evidence question: Which licensed relationship is shown? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Use FDA’s term only for approved products. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for biosimilar is an fda licensure determination, its identifier or version context, and one limit that must remain visible.
CHAPTER 5 OF 17 · Read the relationship
5. Interchangeable is an additional designation
Biological products need their own licensure and relationship map because they are not described through the Orange Book pathway. An interchangeable biosimilar meets additional statutory requirements and is identified as interchangeable with its reference product. This supports careful science learning about proteins, manufacturing and regulatory comparison.
Try this
Evidence question: Does the database mark biosimilar or interchangeable? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Copy the exact relationship. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for interchangeable is an additional designation, its identifier or version context, and one limit that must remain visible.
CHAPTER 6 OF 17 · Read the relationship
6. Interchangeability does not mean superior efficacy
The Purple Book lists FDA-licensed biological products and connects biosimilars and interchangeable biosimilars with reference products. The designation concerns the regulatory standard and potential pharmacy substitution subject to applicable law; it does not mean a product is clinically better. It also separates product licensure from prescribing or state substitution practice.
Try this
Evidence question: Which claim would overstate the designation? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Replace comparative adjectives with the FDA status. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for interchangeability does not mean superior efficacy, its identifier or version context, and one limit that must remain visible.
Biosimilarity and interchangeability are defined regulatory determinations, not casual claims that two products are simply alike. Automatic substitution practices for interchangeable products can depend on US state law and professional rules. The Purple Book itself does not decide an individual substitution. The database card is a route into FDA information rather than a personal treatment recommendation.
Try this
Evidence question: Which legal and clinical context remains? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Refer patient questions to a pharmacist or prescriber. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for state law affects pharmacy substitution, its identifier or version context, and one limit that must remain visible.
Product identity, application, licensure date and relationship should remain in the same note. Search results can group products sharing a core name and use visual cues to show biosimilar or interchangeable relationships. Product suffixes and proprietary names still distinguish entries. A current access date matters because new products and relationships are added.
Try this
Evidence question: Which exact product card is being read? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Record core name, suffix and proprietary name. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for core names group related products, its identifier or version context, and one limit that must remain visible.
CHAPTER 9 OF 17 · Check the licence record
9. Application numbers identify licence records
Biological products need their own licensure and relationship map because they are not described through the Orange Book pathway. Biologic License Application numbers and supplement information help distinguish regulatory files and product presentations. This supports careful science learning about proteins, manufacturing and regulatory comparison.
Try this
Evidence question: Which BLA number supports the record? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Keep application and product names together. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for application numbers identify licence records, its identifier or version context, and one limit that must remain visible.
The Purple Book lists FDA-licensed biological products and connects biosimilars and interchangeable biosimilars with reference products. The original licensure date belongs to the specific product and application. Later supplements or additional presentations can have separate context. It also separates product licensure from prescribing or state substitution practice.
Try this
Evidence question: Which date and action are shown? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Avoid turning licensure date into launch date. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for licensure dates mark fda action, its identifier or version context, and one limit that must remain visible.
Biosimilarity and interchangeability are defined regulatory determinations, not casual claims that two products are simply alike. Biological products can have multiple strengths, dosage forms, routes or presentations. Relationship claims should match the listed product. The database card is a route into FDA information rather than a personal treatment recommendation.
Try this
Evidence question: Which presentation is relevant? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Compare complete product details. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for presentations and strengths matter, its identifier or version context, and one limit that must remain visible.
CHAPTER 12 OF 17 · Check the licence record
12. CDER and CBER cover different biologic categories
Product identity, application, licensure date and relationship should remain in the same note. Purple Book coverage includes CDER therapeutic biologics and CBER-regulated allergenic, cellular and gene therapy, hematologic and vaccine products. A current access date matters because new products and relationships are added.
Try this
Evidence question: Which center regulates this record? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Name the center before generalising. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for cder and cber cover different biologic categories, its identifier or version context, and one limit that must remain visible.
CHAPTER 13 OF 17 · Preserve clinical and legal limits
13. Reference-product exclusivity is a separate field
Biological products need their own licensure and relationship map because they are not described through the Orange Book pathway. Purple Book information can include reference-product exclusivity determinations where applicable. Exclusivity does not define biosimilarity. This supports careful science learning about proteins, manufacturing and regulatory comparison.
Try this
Evidence question: Which field and date are actually shown? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Keep licensure relationship and exclusivity separate. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for reference-product exclusivity is a separate field, its identifier or version context, and one limit that must remain visible.
CHAPTER 14 OF 17 · Preserve clinical and legal limits
14. Patent information has a defined source
The Purple Book lists FDA-licensed biological products and connects biosimilars and interchangeable biosimilars with reference products. The database explains that it publishes only patent information provided to FDA by reference-product sponsors for certain licensed biological products. It also separates product licensure from prescribing or state substitution practice.
Try this
Evidence question: Who supplied the listed patent information? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: State the coverage boundary. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for patent information has a defined source, its identifier or version context, and one limit that must remain visible.
CHAPTER 15 OF 17 · Preserve clinical and legal limits
15. Advanced search filters shape the set
Biosimilarity and interchangeability are defined regulatory determinations, not casual claims that two products are simply alike. Users can search across products and filter by fields such as applicant or product attributes. Counts depend on the query and current database. The database card is a route into FDA information rather than a personal treatment recommendation.
Try this
Evidence question: Which filters produced the list? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the search state and date. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for advanced search filters shape the set, its identifier or version context, and one limit that must remain visible.
CHAPTER 16 OF 17 · Preserve clinical and legal limits
16. A database relationship is not a prescribing decision
Product identity, application, licensure date and relationship should remain in the same note. Purple Book shows regulatory identity and relationships. Patient-specific use depends on approved labeling, condition, clinician judgement and other evidence. A current access date matters because new products and relationships are added.
Try this
Evidence question: What question cannot the database answer alone? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Separate information retrieval from treatment advice. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for a database relationship is not a prescribing decision, its identifier or version context, and one limit that must remain visible.
CHAPTER 17 OF 17 · Preserve clinical and legal limits
17. Biosimilar literacy supports modern science careers
Biological products need their own licensure and relationship map because they are not described through the Orange Book pathway. Biochemists, manufacturing scientists, pharmacists, clinicians and regulators work across analytical, functional, clinical and regulatory evidence. This supports careful science learning about proteins, manufacturing and regulatory comparison.
Try this
Evidence question: Which evidence layer established the relationship? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Create a reference-biosimilar-interchangeability receipt. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for biosimilar literacy supports modern science careers, its identifier or version context, and one limit that must remain visible.
Contents · Previous chapter · Continue at the Science Learning Hub
A biologic relationship stays clear when product identity and FDA status remain together
The Purple Book helps learners see how reference products, biosimilars and interchangeable biosimilars are connected in the US licensure system. It also covers a wider set of licensed biologics regulated by CDER and CBER.
Save the proper and proprietary names, suffix where applicable, applicant, BLA number, FDA center, product presentation, original licensure date, reference relationship, biosimilar or interchangeable designation, exclusivity or patent field, query and access date.
| Reading object | What it can support | Question to keep visible |
|---|---|---|
| Reference product | Fully licensed comparator for biosimilar review | Which product and BLA apply? |
| Biosimilar | Licensed as highly similar with no clinically meaningful differences | Which reference product? |
| Interchangeable biosimilar | Biosimilar meeting additional statutory requirements | What exact designation is shown? |
| Purple Book record | FDA product and relationship entry | Which center, date and presentation? |
Sources and next reading
Substantive resource claims in this article were checked against the primary pages below. A structured record is a route into evidence; it does not by itself prove a scientific conclusion. Recheck the live record, evidence labels and release context before using it in assessed work or research.
For a classroom enquiry, save a short research receipt containing the question, search terms, selected object, exact identifier, version, access date and the evidence boundary you observed. Add the file or page that supports each statement. This small routine turns browsing into accountable science learning and gives a teacher, classmate or future analyst a route they can independently follow.
Before sharing the conclusion, ask another reader to retrace the route without verbal hints. If they reach a different version, file or interpretation, improve the receipt and narrow the claim. Reproducibility begins with this practical check. It teaches careful reading, supports fair collaboration and keeps uncertainty visible while evidence moves from an online service into notes, analysis and a final explanation.
A useful final review separates five questions. What object was found? Which organisation or repository maintains it? What exact evidence was inspected? Which statement does that evidence support? What remains uncertain? Answer each question in one sentence, then connect every answer to a visible field, file or source page. This review catches common mistakes: citing a collection when a file supplied the value, treating the newest release as the analysed release, confusing permission with scientific suitability, or turning a discovery count into a conclusion. It also gives students a calm way to improve work. A missing detail becomes a next research step instead of an invitation to guess. When the route is complete, the final explanation can stay simple because the identifiers, dates, versions, limitations and supporting evidence are already organised underneath it.
Primary sources
- FDA Purple Book Search — accessed 25 October 2026.
- About the Purple Book — accessed 25 October 2026.
- Purple Book FAQs — accessed 25 October 2026.
- FDA biosimilar product information — accessed 25 October 2026.
- FDA Purple Book overview — accessed 25 October 2026.